Allurion Announces Positive Topline Results From AUDACITY Trial

NATICK, Mass., January 08, 2025–Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug Administration (FDA) pivotal trial evaluating the safety and efficacy of the Allurion Balloon.

This article was originally published here.